Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 27, Issue 9, Pages 1804-1817Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2019.03.028
Keywords
Oxindole derivatives; Indolin-2-one; GSK3 beta; Glycogen synthase kinase 3; Antidiabetic; 3-Substituted indolinone; Anticancer
Funding
- Russian Foundation for Basic Research (RFBR), Russia [17-03-01320]
- Council on grants of the President of the Russian Federation [SP-595.2018.4]
Ask authors/readers for more resources
Glycogen synthase kinase 3 beta (GSK-3 beta) is a widely investigated molecular target for numerous diseases including Alzheimer's disease, cancer, and diabetes mellitus. Inhibition of GSK-3 beta activity has become an attractive approach for treatment of diabetes and cancer. We report the discovery of novel GSK-3 beta inhibitors of 3-arylidene-2-oxindole scaffold with promising activity. The most potent compound 3a inhibits GSK-3 beta with IC(50 )4.19 nM. In a cell-based assay 3a shows no significant leucocyte toxicity at 10 mu M and is moderately cytotoxic against A549 cells. Compound 3a demonstrated high antidiabetic efficacy in obese streptozotocin-treated rats improving glucose tolerance at a dose of 50 mg/kg body weight thus representing an interesting lead for further optimization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available